We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.

Search results

Order by: most recent most popular relevance

Results:1-10 of 52

Transferring marketing authorizations as a result of Brexit: key tax considerations
  • Baker McKenzie
  • United Kingdom, European Union
  • October 18 2018

Developing, producing and marketing medicinal products involves a significant amount of regulation grounded in EU law for pharmaceutical companies to

Parallel import of medicinal products - when a name change is a game changer
  • Hogan Lovells
  • Italy
  • October 10 2018

The Lazio Administrative Court recently decided that, as a rule, parallel importers of medicinal products have no right to change the trademark

EU: Falsified Medicines Directive: Implications for parallel importers and of Brexit
  • AA Thornton & Co
  • United Kingdom, European Union
  • October 4 2018

Directive 201162EU, better known as "The Falsified Medicines Directive" or "FMD", came into force on 2 January 2013, with the aim of preventing

Importing Medical Devices in Egypt
  • Youssry Saleh & Partners
  • Egypt
  • September 23 2018

Medical Devices are used in the healthcare for the diagnosis, prevention, monitoring or treatment of illness or disability. The Egyptian Ministry of

Dismissal of the preliminary injunction request based on SPC covering the combination of ezetimibe and simvastatin
  • France
  • July 6 2018

Interpretation of articles 3 (c) and 3 (d) of Regulation (EC) No. 4692009 The Paris Court of Appeal uphold the Interim Order of the Paris Court of

Shire v EMA: Clarification on orphan designation for products with the same active substance
  • CMS
  • European Union
  • April 24 2018

On 22 March 2018 the EU General Court handed down its judgment in Case T-8016 Shire Pharmaceuticals Ireland Ltd v European Medicines Agency (EMA)

EMA’s pre-authorisation procedural advice for the centralised procedure updated
  • Hogan Lovells
  • European Union
  • February 27 2018

The European Medicines Agency (“EMA”) has published an updated version of the guidance document on pre-authorisation for users of the centralised

Patents: supplementary protection certificates
  • Bird & Bird
  • European Union
  • February 9 2018

The European Court of Justice (ECJ) has ruled that only a granted marketing authorisation could be used to apply for a supplementary protection

CJEU confirms the rules for rectifying SPC duration
  • Simmons & Simmons LLP
  • European Union
  • January 5 2018

To bring last year to a close and hand down its second supplementary protection certificate (SPC) decision of December 2017, the Court of Justice of

News Update EU - Life Sciences Special December 2017
  • Houthoff
  • United Kingdom, European Union, France
  • December 7 2017

On 20 November 2017, the EU Council announced that Amsterdam will be the new location for the European Medicines Agency (EMA) after the UK will